162 terminated. 162 Phase 2, 26 Phase 1, 5 Phase 3.
By phase and status
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Trials (filtered) newest first · largest first
All 162 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis Dupilumab, Placebo, IBI356 - Atopic Dermatitis | Phase 2 | Terminated | 18 | 2025-12-31 | 2026-10-27 |
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) Dupilumab, JNJ-95475939, Placebo - Dermatitis, Atopic | Phase 2 | Terminated | 256 | 2025-02-26 | 2026-07-31 |
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment - Chronic Urticaria, Idiopathic, Hidradenitis | Phase 2 | Terminated | 73 | 2025-01-02 | 2026-02-03 |
A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials Briquilimab - Urticaria Chronic | Phase 2 | Terminated | 67 | 2024-11-26 | 2026-08-06 |
Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis. GSK1070806, Placebo - Dermatitis, Atopic | Phase 2 | Terminated | 79 | 2024-06-05 | 2026-06-16 |
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma Rocatinlimab, Placebo - Asthma | Phase 2 | Terminated | 317 | 2024-05-24 | 2026-08-11 |
A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines Briquilimab - Chronic Inducible Urticaria | Phase 1 / Phase 2 | Terminated | 27 | 2024-03-18 | 2025-10-08 |
Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy Experimental: CHF6001 3200 μg, Placebo Comparator: CHF6001 Placebo - Uncontrolled Asthma | Phase 2 | Terminated | 517 | 2023-11-26 | 2025-12-18 |
A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis GSK1070806, Placebo - Dermatitis, Atopic | Phase 2 | Terminated | 161 | 2023-11-16 | 2026-06-03 |
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis SAR444656 (KT-474), Placebo - Atopic Dermatitis | Phase 2 | Terminated | 70 | 2023-11-09 | 2026-11-03 |
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria Oral EP262, Placebo - Chronic Spontaneous Urticaria | Phase 2 | Terminated | 113 | 2023-09-25 | 2025-12-19 |
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Amlitelimab, Placebo - Asthma | Phase 2 | Terminated | 335 | 2023-09-05 | 2026-10-02 |
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) Placebo, IMG-007 - Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis | Phase 1 / Phase 2 | Terminated | 13 | 2023-08-09 | 2025-11-06 |
Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma RPT193, Placebo - Asthma | Phase 2 | Terminated | 38 | 2023-07-05 | 2026-03-23 |
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis LY3454738, Placebo - Atopic Dermatitis | Phase 2 | Terminated | 234 | 2023-06-21 | 2025-12-02 |
Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA Itraconazole Powder, Placebo - ABPA | Phase 2 | Terminated | 8 | 2023-02-01 | 2024-04-02 |
A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection etrasimod, Placebo - Atopic Dermatitis, Atopic Dermatitis, Unspecified | Phase 2 / Phase 3 | Terminated | 58 | 2023-01-18 | 2025-05-08 |
A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis BMX-010, Placebo - Atopic Dermatitis | Phase 2 | Terminated | 103 | 2023-01-08 | 2024-04-18 |
A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria Lirentelimab (AK002), Placebo - Chronic Spontaneous Urticaria | Phase 2 | Terminated | 127 | 2022-10-26 | 2024-09-27 |
A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis Namilumab, Placebo - Sarcoidosis, Pulmonary | Phase 2 | Terminated | 107 | 2022-08-31 | 2025-09-12 |
Showing 20 of 162. Sign in to see all of them.
Narrower conditions
Asthma (58) · Dermatitis, Atopic (45) · Eczema (13) · Urticaria (12) · Chronic Urticaria (9) · Dermatitis (8) · Food Hypersensitivity (7) · Pruritus (7) · Sarcoidosis (7) · Immune System Diseases (6) · Rhinitis, Allergic (5) · Skin Diseases (5) · Eosinophilic Esophagitis (4) · Lymphoma, Follicular (4)
Broader conditions
Immune System Diseases (156) · Hypersensitivity, Immediate (142) · Respiratory Tract Diseases (71) · Skin and Connective Tissue Diseases (68) · Lung Diseases (67) · Respiratory Hypersensitivity (65) · Skin Diseases (63) · Bronchial Diseases (58) · Lung Diseases, Obstructive (58) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (51) · Genetic Diseases, Inborn (51) · Skin Diseases, Genetic (48) · Skin Diseases, Eczematous (44) · Dermatitis (39)
Interventions
dupilumab (5) · Fluticasone (3) · AK002 (2) · Azithromycin (2) · Bosentan (2) · Epinephrine (2) · GSK1070806 (2) · Omalizumab (2) · Rituximab (2) · Therapeutics (2) · benralizumab (2) · bermekimab (2) · enokizumab (2) · itepekimab (2) · ligelizumab (2)
Sponsors
Novartis Pharmaceuticals (11) · GlaxoSmithKline (5) · AstraZeneca (4) · Boehringer Ingelheim (4) · Johns Hopkins University (4) · Amgen (3) · Eli Lilly and Company (3) · Janssen Research & Development, LLC (3) · MedImmune LLC (3) · Pfizer (3) · Regeneron Pharmaceuticals (3) · University of Chicago (3) · Allakos Inc. (2) · Amphastar Pharmaceuticals, Inc. (2) · DermBiont, Inc. (2)
Countries
United States (109) · Germany (44) · Poland (40) · Canada (37) · United Kingdom (26) · France (19) · Spain (19) · Czechia (18) · Japan (18) · South Korea (16) · Hungary (15) · Australia (14) · Bulgaria (14) · Argentina (12) · Belgium (11)
Top investigators
Chin Lee, MD, MPH (2) · Joseph Parker, M.D. (2) · Alessio Fasano, M. D. (1) · Alex Zvulunov, Prof (1)
Results publications
PMID 39077906, PMID 12384926, PMID 15201414, PMID 15334472, PMID 16899778, PMID 17478385, PMID 18645136, PMID 21356110, PMID 21945511, PMID 22294344, PMID 23234805, PMID 23949578, PMID 24751453, PMID 25223501, PMID 27143789, PMID 28118536, PMID 32150492, PMID 32840597, PMID 33006765, PMID 33032168, PMID 33293212, PMID 33314326, PMID 33397449, PMID 33831327, PMID 34048641, PMID 34326185, PMID 36735745, PMID 37951310, PMID 37965347, PMID 38814736, PMID 39393433, PMID 40766832, PMID 41200192, PMID 41819539, PMID 41865746
NIH funding
2018 (10), 2023 (5), 2017 (2), 2019 (2), 2008 (1), 2009 (1), 2014 (1), P01AT002647 (1), R21AT004089 (1), U01AI140498 (1), U01HL119952 (1), ZIAAR041138-08 (1)